$RIGL
RIGEL PHARMACEUTICALS INC

2021 Q4 Form 10-K Financial Statement

#000155837022002551 Filed on March 01, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $20.41M $149.2M $18.45M
YoY Change 10.62% 37.39% 19.81%
Cost Of Revenue $487.0K $1.083M $320.0K
YoY Change 52.19% 21.01% 77.78%
Gross Profit $19.92M $148.2M $17.43M
YoY Change 14.28% 37.53% 27.7%
Gross Profit Margin 97.61% 99.27% 94.48%
Selling, General & Admin $24.52M $91.89M $21.82M
YoY Change 12.35% 19.97% 19.17%
% of Gross Profit 123.05% 62.02% 125.17%
Research & Development $13.30M $65.24M $15.14M
YoY Change -12.13% 8.55% 6.25%
% of Gross Profit 66.78% 44.03% 86.85%
Depreciation & Amortization $404.0K $1.200M $210.0K
YoY Change 92.38% 71.43% 16.67%
% of Gross Profit 2.03% 0.81% 1.2%
Operating Expenses $37.82M $157.1M $36.96M
YoY Change 2.32% 14.94% 13.51%
Operating Profit -$17.90M -$12.50M -$19.53M
YoY Change -8.35% -56.87% 3.27%
Interest Expense -$1.283M $4.860M -$410.0K
YoY Change 212.93% 259.2% -392.86%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$22.70M -$17.31M -$19.24M
YoY Change 17.99% -41.81% 11.86%
Income Tax -$60.00K $600.0K
% Of Pretax Income
Net Earnings -$22.64M -$17.91M -$19.24M
YoY Change 17.68% -39.77% 11.86%
Net Earnings / Revenue -110.94% -12.0% -104.28%
Basic Earnings Per Share -$0.11
Diluted Earnings Per Share -$132.3K -$0.11 -$113.8K
COMMON SHARES
Basic Shares Outstanding 171.0M 170.5M 169.0M
Diluted Shares Outstanding 170.5M 169.0M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $125.0M $125.0M $57.30M
YoY Change 118.09% 118.09% -41.59%
Cash & Equivalents $18.89M $18.89M $30.37M
Short-Term Investments $106.1M $106.1M $27.00M
Other Short-Term Assets $7.412M $7.412M $14.00M
YoY Change -47.06% -47.06% 47.37%
Inventory $6.616M $6.616M $1.638M
Prepaid Expenses
Receivables $15.47M $15.47M $15.97M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $154.5M $154.5M $88.98M
YoY Change 73.59% 73.56% -25.23%
LONG-TERM ASSETS
Property, Plant & Equipment $2.184M $11.89M $2.676M
YoY Change -18.39% -42.3% 23.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $974.0K $974.0K $824.0K
YoY Change 18.2% 21.75% 18.39%
Total Long-Term Assets $12.86M $12.86M $21.40M
YoY Change -39.89% -39.9% -25.1%
TOTAL ASSETS
Total Short-Term Assets $154.5M $154.5M $88.98M
Total Long-Term Assets $12.86M $12.86M $21.40M
Total Assets $167.3M $167.3M $110.4M
YoY Change 51.6% 51.57% -25.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.795M $3.795M $3.707M
YoY Change 2.37% 2.57% -10.72%
Accrued Expenses $3.580M $43.66M $3.661M
YoY Change -2.21% 28.03% 29.09%
Deferred Revenue $2.596M $3.018M
YoY Change -13.98% -88.07%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $63.55M $63.55M $40.84M
YoY Change 55.61% 55.77% -29.84%
LONG-TERM LIABILITIES
Long-Term Debt $19.91M $19.91M $19.80M
YoY Change 0.58% 0.58% 102.04%
Other Long-Term Liabilities $52.73M $53.49M $5.045M
YoY Change 945.13% 240.68% -1.04%
Total Long-Term Liabilities $52.73M $73.40M $5.045M
YoY Change 945.13% 106.76% -1.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $63.55M $63.55M $40.84M
Total Long-Term Liabilities $52.73M $73.40M $5.045M
Total Liabilities $116.3M $137.0M $45.89M
YoY Change 153.41% 79.26% -27.52%
SHAREHOLDERS EQUITY
Retained Earnings -$1.324B -$1.306B
YoY Change 1.37% 2.33%
Common Stock $1.354B $1.340B
YoY Change 1.07% 0.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.37M $30.37M $34.03M
YoY Change
Total Liabilities & Shareholders Equity $167.3M $167.3M $110.4M
YoY Change 51.6% 51.57% -25.2%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$22.64M -$17.91M -$19.24M
YoY Change 17.68% -39.77% 11.86%
Depreciation, Depletion And Amortization $404.0K $1.200M $210.0K
YoY Change 92.38% 71.43% 16.67%
Cash From Operating Activities -$19.09M $5.878M -$15.58M
YoY Change 22.5% -111.26% 61.45%
INVESTING ACTIVITIES
Capital Expenditures $21.00K $627.0K -$500.0K
YoY Change -104.2% -50.32% -19.35%
Acquisitions
YoY Change
Other Investing Activities $6.467M -$79.41M $9.220M
YoY Change -29.86% -262.96% -231.71%
Cash From Investing Activities $6.488M -$80.04M $8.710M
YoY Change -25.51% -268.62% -214.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.085M 62.68M 670.0K
YoY Change 61.94% 398.57% -4.29%
NET CHANGE
Cash From Operating Activities -19.09M 5.878M -15.58M
Cash From Investing Activities 6.488M -80.04M 8.710M
Cash From Financing Activities 1.085M 62.68M 670.0K
Net Change In Cash -11.51M -11.48M -6.200M
YoY Change 85.69% -246.24% -62.58%
FREE CASH FLOW
Cash From Operating Activities -$19.09M $5.878M -$15.58M
Capital Expenditures $21.00K $627.0K -$500.0K
Free Cash Flow -$19.11M $5.251M -$15.08M
YoY Change 26.7% -109.82% 67.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
170492000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
168754000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
167400000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
170492000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
168754000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
167400000
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001034842
CY2021 dei Entity Registrant Name
EntityRegistrantName
RIGEL PHARMACEUTICALS INC
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
CY2020 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
CY2019 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
169316782
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
171602226
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2021 dei City Area Code
CityAreaCode
650
CY2021 dei Local Phone Number
LocalPhoneNumber
624-1100
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
171602226
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
169316782
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y0M29D
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M7D
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
000-29889
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3248524
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
1180 Veterans Blvd.
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $.001 per share
CY2021 dei Trading Symbol
TradingSymbol
RIGL
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
740000000.0
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
171683545
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
San Francisco, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18890000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30373000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
106077000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
26954000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15472000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15973000
CY2021Q4 us-gaap Inventory Net
InventoryNet
6616000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1638000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7412000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14045000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
154467000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
88983000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2184000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2676000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9703000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17895000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
974000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
824000
CY2021Q4 us-gaap Assets
Assets
167328000
CY2020Q4 us-gaap Assets
Assets
110378000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3795000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3707000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10690000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9592000
CY2021Q4 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
10384000
CY2020Q4 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
4889000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12691000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11014000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9892000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8621000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2596000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3018000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13506000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
63554000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40841000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
759000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10651000
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
19914000
CY2020Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
19815000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
52727000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5045000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
171602226
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
169316782
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
172000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
169000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1354190000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1339833000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-102000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1323886000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1305972000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30374000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
34026000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
167328000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
110378000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
149236000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
108621000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59288000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1083000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
895000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
906000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
65237000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
60101000
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
52885000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
91891000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
76598000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
74588000
CY2021 us-gaap Restructuring Charges
RestructuringCharges
3521000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
161732000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
137594000
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
128379000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-12496000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-28973000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-69091000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
47000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
582000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
2532000
CY2021 us-gaap Interest Expense
InterestExpense
4860000
CY2020 us-gaap Interest Expense
InterestExpense
1353000
CY2019 us-gaap Interest Expense
InterestExpense
335000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17309000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29744000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66894000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
605000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-17914000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-29744000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-66894000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
170492000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
168754000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
167400000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17914000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29744000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66894000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-98000
CY2020 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-27000
CY2019 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
47000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18012000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29771000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66847000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
109877000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66894000
CY2019 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
47000
CY2019 rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
-803000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1576000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9209000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
53815000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29744000
CY2020 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-27000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2596000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7386000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
34026000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17914000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-98000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4775000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9585000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30374000
CY2021 us-gaap Profit Loss
ProfitLoss
-17914000
CY2020 us-gaap Profit Loss
ProfitLoss
-29744000
CY2019 us-gaap Profit Loss
ProfitLoss
-66894000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
9486000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7297000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
9115000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1162000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
706000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
683000
CY2021 rigl Noncash Interest Expense
NoncashInterestExpense
3139000
CY2021 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-287000
CY2020 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
122000
CY2019 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1073000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-501000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5862000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6034000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4875000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
126000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
366000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6633000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4583000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5673000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
150000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
128000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-39000
CY2021 rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
8192000
CY2020 rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
7814000
CY2019 rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
7118000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
41000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-331000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2239000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1098000
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
773000
CY2019 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1133000
CY2021 rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
5495000
CY2020 rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
-1071000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
62050000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
130434000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
123126000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5878000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52185000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41510000
CY2021 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
141459000
CY2020 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
81706000
CY2019 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
145327000
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1826000
CY2020 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
4051000
CY2019 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3122000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-8621000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-7230000
CY2019 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-6725000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-422000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-23629000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
24255000
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
5098000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
627000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1262000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1455000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-80036000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
47466000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23656000
CY2021 rigl Cost Share Advance From Collaboration Partner
CostShareAdvanceFromCollaborationPartner
57900000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4775000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2596000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1576000
CY2020 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
9975000
CY2019 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
9789000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62675000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12571000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11365000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11483000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7852000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-53801000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30373000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22521000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76322000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18890000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30373000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22521000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1500000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
1180000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
137000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
125000000.0
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made by management include those relating to revenue recognition on product sales and collaboration agreements, recoverability of our assets, including accounts receivables and inventories, stock-based compensation and the probability of achievement of corporate performance-based milestones for our performance-based stock option awards, impairment issues, the weighted average incremental borrowing rate for our lease, estimated interest rate for our financing liability, the estimated useful life of assets, and estimated accruals, particularly research and development accruals, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. To the extent there are material differences between these estimates and actual results, our financial statements will be affected. </p>
CY2020Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
171000
CY2019Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
109000
CY2018Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
50000
CY2021 rigl Customer Allowance For Prompt Payment Discounts Period Increase
CustomerAllowanceForPromptPaymentDiscountsPeriodIncrease
609000
CY2020 rigl Customer Allowance For Prompt Payment Discounts Period Increase
CustomerAllowanceForPromptPaymentDiscountsPeriodIncrease
807000
CY2019 rigl Customer Allowance For Prompt Payment Discounts Period Increase
CustomerAllowanceForPromptPaymentDiscountsPeriodIncrease
540000
CY2021 rigl Customer Allowance For Prompt Payment Discounts Period Decrease
CustomerAllowanceForPromptPaymentDiscountsPeriodDecrease
674000
CY2020 rigl Customer Allowance For Prompt Payment Discounts Period Decrease
CustomerAllowanceForPromptPaymentDiscountsPeriodDecrease
745000
CY2019 rigl Customer Allowance For Prompt Payment Discounts Period Decrease
CustomerAllowanceForPromptPaymentDiscountsPeriodDecrease
481000
CY2021Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
106000
CY2020Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
171000
CY2019Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
109000
CY2021 rigl Share Based Compensation Arrangement By Share Based Payment Award Options Number Of Homogenous Groups For Determining Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfHomogenousGroupsForDeterminingFairValue
3
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentration of credit risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to a concentration of credit risk are primarily cash, investment in debt securities and accounts receivable. All of our cash and investment in debt securities are maintained with financial institutions that management believes are creditworthy. By policy, we limit the concentration of credit risk by diversifying our investments among a variety of high credit-quality issuers. Due to the short-term nature of these investments, we believe we do not have a material exposure to credit risk arising from our investments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk with respect to our accounts receivable is limited due to our small number of customers. Our accounts receivable consists mostly of outstanding invoices from our sale of TAVALISSE to our three specialty distributors. Accounts receivable may also include outstanding invoice or invoices from our collaboration partners with respect to the related sponsored research and license agreements, as well as outstanding invoice or invoices from the US Government with respect to the related government contract. As of December 31, 2021, 85% of our accounts receivable are outstanding invoices from our three specialty distributors, and the remaining 15% are outstanding invoices from the US Government and from other collaboration partners, Grifols, Kissei and Medison. As of December 31, 2020, 97% of our accounts receivable consisted of outstanding invoices from our specialty distributors, and the remaining 3% was related to outstanding invoices from our collaboration partners, Grifols and Medison.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">See “Note 3 - Revenues” for summary of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations. </p>
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59288000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17914000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29744000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66894000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
170492000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
168754000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
167400000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30235000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27260000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22671000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
149236000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
108621000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
12900000
CY2020Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
6065000
CY2021 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
16788000
CY2021 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
14938000
CY2021Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
7915000
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
3332000
CY2020 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
13330000
CY2020 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
10597000
CY2020Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
6065000
CY2021 rigl Sales Discounts And Allowances
SalesDiscountsAndAllowances
18200000
CY2021 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
16800000
CY2020 rigl Sales Discounts And Allowances
SalesDiscountsAndAllowances
14800000
CY2020 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
13300000
CY2021 rigl Collaborative Arrangement Upfront Fee Received
CollaborativeArrangementUpfrontFeeReceived
125000000.0
CY2021 us-gaap Accretion Expense
AccretionExpense
2800000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9486000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7295000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9115000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
400000
CY2021 rigl Number Of Active Equity Plans
NumberOfActiveEquityPlans
2
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
233750
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5142000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
162000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1189000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1312000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
449000
CY2021Q4 us-gaap Inventory Net
InventoryNet
6616000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1638000
CY2020Q4 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
4000.0
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
124967000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
57327000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18890000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30373000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
106077000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
26954000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
124967000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
57327000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
111978000
CY2021Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
111876000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
35856000
CY2020Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
35852000
CY2021 rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P196D
CY2020 rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P78D
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
39
CY2021 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
88037000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
104000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16735000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16352000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14551000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13676000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2184000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2676000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1200000
CY2021Q4 rigl Sublease Payments To Be Received Next Twelve Months
SubleasePaymentsToBeReceivedNextTwelveMonths
4716000
CY2021Q4 rigl Lessee Operating Lease Liability Net Payments Next Twelve Months
LesseeOperatingLeaseLiabilityNetPaymentsNextTwelveMonths
5769000
CY2017Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
9328
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
10000000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7500000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
20000000
CY2021Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
57000
CY2021 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
100000
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5898000
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4577000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3580000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3661000
CY2021Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
2017000
CY2020Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
1488000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
605000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
204000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1017000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
387000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
271000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
12691000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11014000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2500000
CY2021Q4 rigl Expected Income From Sublease
ExpectedIncomeFromSublease
5100000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9700000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17900000
CY2021Q4 rigl Lease Liability
LeaseLiability
10700000
CY2020Q4 rigl Lease Liability
LeaseLiability
19300000
CY2021Q4 us-gaap Incentive To Lessee
IncentiveToLessee
600000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
877000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
10485000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
16297000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
5360000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
5360000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
5248000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
910000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
926000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
745000
CY2021 us-gaap Lease Cost
LeaseCost
6270000
CY2020 us-gaap Lease Cost
LeaseCost
6286000
CY2019 us-gaap Lease Cost
LeaseCost
5993000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
10082000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
9694000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
9321000
CY2021 rigl Fixed Sublease Expense
FixedSubleaseExpense
4381000
CY2020 rigl Fixed Sublease Expense
FixedSubleaseExpense
4381000
CY2019 rigl Fixed Sublease Expense
FixedSubleaseExpense
4381000
CY2021 rigl Variable Sublease Expense
VariableSubleaseExpense
917000
CY2020 rigl Variable Sublease Expense
VariableSubleaseExpense
962000
CY2019 rigl Variable Sublease Expense
VariableSubleaseExpense
829000
CY2021 us-gaap Sublease Income
SubleaseIncome
5298000
CY2020 us-gaap Sublease Income
SubleaseIncome
5343000
CY2019 us-gaap Sublease Income
SubleaseIncome
5210000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1405000
CY2021Q4 rigl Lessee Operating Lease Liability Net Payments Due Year Two
LesseeOperatingLeaseLiabilityNetPaymentsDueYearTwo
483000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11362000
CY2021Q4 rigl Sublease Payments To Be Received
SubleasePaymentsToBeReceived
5110000
CY2021Q4 rigl Lessee Operating Lease Liability Net Payments
LesseeOperatingLeaseLiabilityNetPayments
6252000
CY2021 rigl Operating Lease Rent Expense Net
OperatingLeaseRentExpenseNet
6300000
CY2020 rigl Operating Lease Rent Expense Net
OperatingLeaseRentExpenseNet
6300000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
64252000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
8819000
CY2021Q4 rigl Sublease Payments To Be Received Two Years
SubleasePaymentsToBeReceivedTwoYears
394000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
7760000
CY2021Q4 rigl Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
2564000
CY2020Q4 rigl Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
4399000
CY2021Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
47000
CY2020Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
34000
CY2019 rigl Operating Lease Rent Expense Net
OperatingLeaseRentExpenseNet
6000000.0
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
171602226
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
169316782
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
229364000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
240767000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
66616000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1626000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1765000
CY2021Q4 rigl Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
2335000
CY2020Q4 rigl Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
4084000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
607000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
537000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
322391000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
315761000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
322391000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
315761000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.028
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.275
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.244
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.217
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.056
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.047
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.028
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.140
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.127
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.051
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.027
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.046
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.015
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.036
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6600000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4100000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
21600000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8901000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8358000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8358000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
285000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
543000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
543000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9186000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8901000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8358000

Files In Submission

Name View Source Status
0001558370-22-002551-index-headers.html Edgar Link pending
0001558370-22-002551-index.html Edgar Link pending
0001558370-22-002551.txt Edgar Link pending
0001558370-22-002551-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rigl-20211231.xsd Edgar Link pending
rigl-20211231x10k.htm Edgar Link pending
rigl-20211231x10k003.jpg Edgar Link pending
rigl-20211231x10k004.jpg Edgar Link pending
rigl-20211231x10k_htm.xml Edgar Link completed
rigl-20211231xex10d31.htm Edgar Link pending
rigl-20211231xex10d32.htm Edgar Link pending
rigl-20211231xex10d34.htm Edgar Link pending
rigl-20211231xex10d35.htm Edgar Link pending
rigl-20211231xex23d1.htm Edgar Link pending
rigl-20211231xex31d1.htm Edgar Link pending
rigl-20211231xex31d2.htm Edgar Link pending
rigl-20211231xex32d1.htm Edgar Link pending
rigl-20211231_cal.xml Edgar Link unprocessable
rigl-20211231_def.xml Edgar Link unprocessable
rigl-20211231_lab.xml Edgar Link unprocessable
rigl-20211231_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending